• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    August 4, 2023 - FDA Approves First Oral Treatment for Postpartum Depression

    8/4/23 6:50:31 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SAGE alert in real time by email
    For Immediate Release:
    August 04, 2023

    Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health care provider in certain health care facilities.

    “Postpartum depression is a serious and potentially life-threatening condition in which women experience sadness, guilt, worthlessness—even, in severe cases, thoughts of harming themselves or their child. And, because postpartum depression can disrupt the maternal-infant bond, it can also have consequences for the child’s physical and emotional development,” said Tiffany R. Farchione, M.D., director of the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research. “Having access to an oral medication will be a beneficial option for many of these women coping with extreme, and sometimes life-threatening, feelings.”

    As with other forms of depression, PPD is characterized by sadness and/or loss of interest in activities that one used to enjoy and a decreased ability to feel pleasure. It can present with symptoms such as cognitive impairment, feelings of sadness or inadequacy, loss of energy or suicidal ideation. 

    The efficacy of Zurzuvae for the treatment of PPD in adults was demonstrated in two randomized, double-blind, placebo-controlled, multicenter studies. The trial participants were women with PPD who met the Diagnostic and Statistical Manual of Mental Disorders criteria for a major depressive episode and whose symptoms began in the third trimester or within four weeks of delivery. In Study 1, patients received 50 mg of Zurzuvae or placebo once daily in the evening for 14 days. In Study 2, patients received another zuranolone product that was approximately equal to 40 mg of Zurzuvae or placebo, also for 14 days. Patients in both studies were monitored for at least four weeks after the 14-day treatment. The primary endpoint of both studies was the change in depressive symptoms using the total score from the 17-item Hamilton depression rating scale (HAMD-17), measured at day 15. Patients in the Zurzuvae groups showed significantly more improvement in their symptoms compared to those in the placebo groups. The treatment effect was maintained at Day 42—four weeks after the last dose of Zurzuvae.

    The labeling contains a boxed warning noting that Zurzuvae can impact a person’s ability to drive and perform other potentially hazardous activities. Patients also may not be able to assess their degree of impairment. To reduce the risk of harm, patients should not drive or operate heavy machinery for at least 12 hours after taking Zurzuvae. 

    The most common side effects include drowsiness, dizziness, diarrhea, fatigue, nasopharyngitis (the common cold), and urinary tract infection. Use of Zurzuvae may cause suicidal thoughts and behavior. Zurzuvae may cause fetal harm. Women should use effective contraception while taking, and for one week after taking, Zurzuvae.

    The daily recommended dose for Zurzuvae is 50mg. It should be taken once every day, for 14 days, in the evening with a fatty meal. 

    The FDA granted this application Priority Review and Fast Track designation.

    Approval of Zurzuvae was granted to Sage Therapeutics, Inc.

    Related Information

    Related Information
    • Women and Depression
    • Pregnancy

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.


    Inquiries

    Media:
    April Grant
    202-657-8179
    Consumer:
    888-INFO-FDA

    Get the next $SAGE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SAGE

    DatePrice TargetRatingAnalyst
    3/11/2025$5.00Underperform
    BofA Securities
    11/21/2024$4.00Underperform → Sector Perform
    RBC Capital Mkts
    10/10/2024Mkt Perform
    Raymond James
    10/4/2024$10.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    7/30/2024$16.00 → $10.00Buy → Hold
    TD Cowen
    7/25/2024$18.00 → $12.00Overweight → Neutral
    JP Morgan
    5/29/2024$15.00Neutral
    Robert W. Baird
    5/29/2024$8.00Sell
    Citigroup
    More analyst ratings

    $SAGE
    Financials

    Live finance-specific insights

    See more
    • Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

      Achieved $13.8 million in ZURZUVAE® (zuranolone) collaboration revenue in the first quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 21% increase from the fourth quarter Sustained growth in shipments to women with postpartum depression; Greater than 3,000 shipments in first quarter of 2025 (22% increase from fourth quarter) Cash, cash equivalents, and marketable securities of $424 million as of March 31, 2025; Cash runway expected to support operations to mid-2027 Strategic alternatives review process remains ongoing Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. "We

      4/29/25 4:05:00 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

      Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that it will host a live webcast on Tuesday, April 29, 2025, at 4:30 p.m. ET to review first quarter 2025 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indic

      4/15/25 6:30:00 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates

      Strong first full year of launch with sustained growth in shipments to women with postpartum depression; Nearly 2,500 shipments in fourth quarter of 2024 (21% increase from third quarter) $11.4 million in ZURZUVAE® (zuranolone) collaboration revenue in the fourth quarter of 2024 and $36.1 million for the year ended December 31, 2024 (50% of the net revenues recorded by Biogen) Cash, cash equivalents, and marketable securities of $504 million as of December 31, 2024; Cash runway expected to support operations to mid-2027 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "We are

      2/11/25 4:05:00 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • August 4, 2023 - La FDA aprueba el primer tratamiento oral para la depresión posparto

      For Immediate Release: August 04, 2023 El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó Zurzuvae (zuranolona), el primer medicamento oral indicado para tratar la depresión posparto (DPP) en mujeres adultas. La DPP es un episodio depresivo grave que generalmente ocurre después del parto, pero también puede comenzar durante las últimas etapas

      8/8/23 9:34:19 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 4, 2023 - FDA Approves First Oral Treatment for Postpartum Depression

      For Immediate Release: August 04, 2023 Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health

      8/4/23 6:50:31 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    SEC Filings

    See more
    • SEC Form 10-Q filed by Sage Therapeutics Inc.

      10-Q - Sage Therapeutics, Inc. (0001597553) (Filer)

      4/29/25 4:18:21 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Sage Therapeutics Inc.

      8-K - Sage Therapeutics, Inc. (0001597553) (Filer)

      4/29/25 4:13:02 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Sage Therapeutics Inc.

      DEFA14A - Sage Therapeutics, Inc. (0001597553) (Filer)

      4/24/25 4:20:03 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    Leadership Updates

    Live Leadership Updates

    See more
    • Sage Therapeutics Announces R&D Leadership Transition

      Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company's product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis. "I would like to extend my sincerest gratitude to Laura for her leadership and dedication to advancing innovation for patients with debilitating brain health conditions," said Barry Greene, Chief Executive Officer of

      3/4/25 4:15:00 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics Appoints Jessica Federer to Board of Directors

      Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230316005117/en/Jessica Federer (Photo: Business Wire) "We are thrilled to have Jessica join our Board of Directors. Jessica is a champion for patients and has a track record of innovation in data and digital transformation which will be a key future growth driver for the industry," said Barry Greene, Chief Executive Officer at Sage Therapeutics. "Jessica's innate curiosit

      3/16/23 6:30:00 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer

      Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Laura Gault, MD, Ph.D. as Chief Medical Officer. In her new role, Dr. Gault will focus on advancing Sage's current and emerging product pipeline through all stages of development. "We are thrilled to have Dr. Gault join Sage to lead the development and delivery of our pipeline of potential new medicines and be a partner in our mission to improve the lives of people affected by brain health disorders," said Barry Greene, Chief Executive Officer at Sage Therapeutics. "Dr. Gault's vision, experience and deep commitment to this field of med

      11/1/22 7:30:00 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

      Achieved $13.8 million in ZURZUVAE® (zuranolone) collaboration revenue in the first quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 21% increase from the fourth quarter Sustained growth in shipments to women with postpartum depression; Greater than 3,000 shipments in first quarter of 2025 (22% increase from fourth quarter) Cash, cash equivalents, and marketable securities of $424 million as of March 31, 2025; Cash runway expected to support operations to mid-2027 Strategic alternatives review process remains ongoing Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. "We

      4/29/25 4:05:00 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

      Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that it will host a live webcast on Tuesday, April 29, 2025, at 4:30 p.m. ET to review first quarter 2025 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indic

      4/15/25 6:30:00 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sage Therapeutics Announces R&D Leadership Transition

      Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company's product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis. "I would like to extend my sincerest gratitude to Laura for her leadership and dedication to advancing innovation for patients with debilitating brain health conditions," said Barry Greene, Chief Executive Officer of

      3/4/25 4:15:00 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

      SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

      11/14/24 6:14:58 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

      SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

      11/12/24 4:56:16 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

      SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

      11/12/24 10:34:18 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Quirk Michael C. was granted 2,000 shares, increasing direct ownership by 7% to 29,108 units (SEC Form 4)

      4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

      4/2/25 4:06:40 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Quirk Michael C. claimed ownership of 27,108 shares (SEC Form 3)

      3 - Sage Therapeutics, Inc. (0001597553) (Issuer)

      4/2/25 4:06:25 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Shiferman Gregory L. covered exercise/tax liability with 79 shares, decreasing direct ownership by 0.26% to 30,680 units (SEC Form 4)

      4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

      3/26/25 4:36:43 PM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SAGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities resumed coverage on SAGE Therapeutics with a new price target

      BofA Securities resumed coverage of SAGE Therapeutics with a rating of Underperform and set a new price target of $5.00

      3/11/25 7:43:31 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SAGE Therapeutics upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded SAGE Therapeutics from Underperform to Sector Perform and set a new price target of $4.00

      11/21/24 7:42:56 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on SAGE Therapeutics

      Raymond James resumed coverage of SAGE Therapeutics with a rating of Mkt Perform

      10/10/24 8:30:27 AM ET
      $SAGE
      Biotechnology: Pharmaceutical Preparations
      Health Care